Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

ClinicalTrials.gov ID: NCT06714591

Public ClinicalTrials.gov record NCT06714591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Study identification

NCT ID: NCT06714591
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: SystImmune Inc.; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

BL-M11D1 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2024
Primary completion: Dec 30, 2026
Completion: Mar 29, 2027
Last update posted: Jul 20, 2026

2024 – 2027

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
UCLA Ronald Reagan Medical Center	Los Angeles	California	90095	Recruiting
University of Colorado Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven	New Haven	Connecticut	06511	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60611	Recruiting
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland	21287	Recruiting
START Midwest/The Cancer and Hematology Center	Grand Rapids	Michigan	49546	Recruiting
John Theurer Cancer Center-Hackensack	Hackensack	New Jersey	07601	Recruiting
Oncology Hematology Care Clinical Trials, LLC	Cincinnati	Ohio	45236	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
WVCI Oncology Associates of Oregon	Eugene	Oregon	24224	Recruiting
Oregon Health and Science University	Portland	Oregon	97239	Recruiting
Temple Health Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
SCRI -TriStar BMT	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06714591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 20, 2026 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06714591 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →